Some genes were more frequently mutated in prostate cancers from Black men, but the researchers said that social inequities also lead to poorer health outcomes.
The company will test samples from women treated with an investigational combination of AstraZeneca's PARP inhibitor olaparib and immunotherapy tremelimumab.
The group published results showing its method can faithfully recapitulate genome-wide measures of DNA repair deficiency using much smaller sequencing panels.
The test is approved to gauge germline BRCA mutations in advanced breast cancer patients who may benefit from treatment with Pfizer's PARP inhibitor Talzenna.
A team led by Walter and Eliza Hall Institute researchers found that ovarian tumors with complete BRCA1 methylation and silencing were more susceptible to treatment.
Informaticians at Spain's National Cancer Research Centre develop a methodology for evaluating likely drug efficacy based on specific patient genotypes.
Researchers used CRISPR-Cas9 screening assays in mouse and human cells to track down point mutations in the PARP1 gene that boost resistance to PARP inhibitor drugs.
The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.
